650 results match your criteria Dystonia Tardive


Response to Letter to the Editor.

Tremor Other Hyperkinet Mov (N Y) 2019 6;9:630. Epub 2019 Feb 6.

Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, US.

In Response To: Walker RH. Reply to: Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/0rjw-cv10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377913PMC
March 2019
3 Reads

Reply to: Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Authors:
Ruth H Walker

Tremor Other Hyperkinet Mov (N Y) 2019 13;9:626. Epub 2019 Feb 13.

Department of Neurology, James J. Peters Veterans Affairs Medical Center, Bronx, New York, NY, US.

In Response To: D'Abreu A, Friedman JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review. Tremor Other Hyperkinet Mov. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7916/3rez-p096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377912PMC
March 2019
1 Read

Antipsychotics for patients with pain.

Korean J Pain 2019 Jan 2;32(1):3-11. Epub 2019 Jan 2.

Department of Anesthesia and Pain Medicine, Pusan National University, Busan, Korea.

Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3344/kjp.2019.32.1.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333575PMC
January 2019
7 Reads

A Case of Pseudodystonia in a Patient on Neuroleptics.

Mov Disord Clin Pract 2018 Sep-Oct;5(5):557-558. Epub 2018 Jul 19.

Department of Neurology-neurophysiology IBN Rochd University Health Center, Casablanca, Morocco; Faculty of Medicine and Pharmacy of Casablanca Morocco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207121PMC
July 2018
2 Reads

Setting the record straight: The nosology of tardive syndromes.

Parkinsonism Relat Disord 2018 Nov 28. Epub 2018 Nov 28.

Department of Neurology, Loma Linda University Medical Center, Loma Linda, CA, USA.

We propose the use of the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements and the analogous repetitive movements of the limbs, trunk, or pelvis. The term tardive syndrome is an umbrella term to be used to refer to the spectrum of all persistent hyperkinetic, hypokinetic, and sensory phenomenologies resulting from chronic dopamine receptor blocking agent (DRBA) exposure. TD is a type of TS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183052
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.11.025DOI Listing
November 2018
3 Reads

Staged bilateral pallidotomy for dystonic camptocormia: case report.

J Neurosurg 2018 Oct 1:1-4. Epub 2018 Oct 1.

Camptocormia is a rare, involuntary movement disorder, presenting as truncal flexion while standing or walking, and is mainly observed as a feature of Parkinson's disease (PD) and primary dystonia. Deep brain stimulation (DBS) of the globus pallidus internus is effective for refractory camptocormia observed with PD or dystonia. However, the effectiveness of pallidotomy for camptocormia has not been investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.5.JNS1840DOI Listing
October 2018
28 Reads

Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports.

Clin Case Rep 2018 Nov 26;6(11):2150-2155. Epub 2018 Sep 26.

Department of Neurology and Clinical Neurophysiology (Dystonia Clinic) Bispebjerg University Hospital University of Copenhagen Copenhagen Denmark.

Tardive dystonia is a risk factor in medical antipsychotic treatment. It often begins with repetitive involuntary jaw and tongue movements resulting in impaired chewing and detrimental effect on the dentition. The orofacial dysfunction may go unrecognized in a neurological setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230632PMC
November 2018
2 Reads

A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.

Agri 2018 Oct;30(4):199-201

Department of Anesthesiology and Reanimation, Zile State Hospital, Tokat, Turkey.

Tardive dyskinesia and tardive dystonia are caused by dopamine receptor blocking agents, mostly antipsychotics and sometimes antidepressants or calcium channel blockers. Duloxetine is a serotonin-noradrenaline reuptake inhibitor used in the treatment of diabetic neuropathic pain and fibromyalgia, as well as major depression. In this case, we aimed to discuss the tardive dyskinesia-like appearance of a patient using duloxetine due to fibromyalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5505/agri.2018.60134DOI Listing
October 2018
21 Reads

Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial.

Brain Stimul 2018 Nov - Dec;11(6):1368-1377. Epub 2018 Sep 11.

Department of Neurology and Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany.

Introduction: Growing evidence suggests that pallidal deep brain stimulation represents a potential new therapeutic avenue in tardive dystonia/dyskinesia, but controlled and blinded randomized studies (RCT) are missing. The present RCT compares dystonia/dyskinesia severity of pallidal neurostimulation in patients with tardive dystonia using a delayed-start design paradigm.

Methods: Dystonia/dyskinesia severity was assessed via blinded videos following pallidal neurostimulation at 3 (blinded phase) and 6 months (open extension phase). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2018.08.006DOI Listing
September 2018
6 Reads

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Nicotine Tob Res 2019 Feb;21(3):357-369

Center for Health Sciences, SRI International, Menlo Park, CA.

Emerging studies indicate that striatal cholinergic interneurons play an important role in synaptic plasticity and motor control under normal physiological conditions, while their disruption may lead to movement disorders. Here we discuss the involvement of the cholinergic system in motor dysfunction, with a focus on the role of the nicotinic cholinergic system in Parkinson's disease and drug-induced dyskinesias. Evidence for a role for the striatal nicotinic cholinergic system stems from studies showing that administration of nicotine or nicotinic receptor drugs protects against nigrostriatal degeneration and decreases L-dopa-induced dyskinesias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ntr/nty063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379038PMC
February 2019
8 Reads
3.296 Impact Factor

Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate.

Clin Neuropharmacol 2018 Sep/Oct;41(5):194-196

Clinical Neurology Unit I, Department of Medicine, San Paolo University Hospital ASST Santi Paolo e Carlo.

Hyperkinetic movement disorders may be difficult to treat, but cases where patients respond to alcohol and/or drugs with similar effects have been described. We report the case of a 64-year-old man with tardive dyskinesia characterized by severe uncontrolled dystonic and myoclonic jerks of the face, shoulders, and arm and forearm muscles, which improved with oral sodium oxybate. Our case suggests the possibility to test sodium oxybate in patients with severe, drug-resistant hyperkinetic syndromes, especially when they are known to improve with alcohol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000290DOI Listing
December 2018
20 Reads

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis.

Can J Psychiatry 2018 Jan 1:706743718777392. Epub 2018 Jan 1.

1 Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0706743718777392
Publisher Site
http://dx.doi.org/10.1177/0706743718777392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299187PMC
January 2018
10 Reads

Antipsychotic-Induced Pisa Syndrome: A 2-Year Follow-up Study.

Authors:
Yen-Feng Lee

Clin Neuropharmacol 2018 Mar/Apr;41(2):60-63

Objectives: Pisa syndrome is characterized by lateral trunk flexion. It is an uncommon adverse drug reaction in patients on antipsychotic medication. Although Pisa syndrome has been reported in patients on antipsychotic treatment, previous studies have not discussed the prognosis of patients with Pisa syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000274DOI Listing
November 2018
10 Reads

Tardive syndromes.

J Neurol Sci 2018 06 5;389:35-42. Epub 2018 Feb 5.

Parkinson's Disease and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States. Electronic address:

Tardive syndromes are a group of hyperkinetic and hypokinetic movement disorders that occur after some delay following exposure to dopamine receptor blocking agents such as antipsychotic and anti-emetic drugs. The severity of these disorders ranges from mild to disabling or even life-threatening. There is a wide range of recognized tardive phenomenologies that may occur in isolation or in combination with each other. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.005DOI Listing
June 2018
6 Reads

Asymmetric Drug-Induced Parkinsonism and Psychopathology: A Prospective Naturalistic Study in Long-Stay Psychiatric Patients.

Front Psychiatry 2018 5;9:18. Epub 2018 Feb 5.

Psychiatric Center GGz Centraal, Amersfoort, Netherlands.

Background: Drug-induced parkinsonism (DIP) is the most common movement disorder induced by antipsychotics. Although DIP is mostly symmetric, asymmetric DIP is reported in a substantial part of the patients. We investigated the frequency of motor asymmetry in DIP and its relationship to the severity of psychopathology in long-stay psychiatric patients. Read More

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fpsyt.2018.00
Publisher Site
http://dx.doi.org/10.3389/fpsyt.2018.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807329PMC
February 2018
20 Reads

Historical perspectives on tardive dyskinesia.

J Neurol Sci 2018 06 3;389:4-9. Epub 2018 Feb 3.

University of Edinburgh, The Royal Edinburgh Hospital, Edinburgh EH10 5HF, Scotland, UK. Electronic address:

Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with dopamine receptor blocking agents including antipsychotic medications. Although uncertainty and concern about this drug side effect have vacillated since its initial recognition 60 years ago, recent commercial interest in developing effective treatments has rekindled scientific and clinical interest after a protracted period of neglect. Although substantial research has advanced knowledge of the clinical features and epidemiology of TD, many fundamental questions raised by early investigators remain unresolved. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.015DOI Listing
June 2018
10 Reads

Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.

J Neurol Sci 2018 06 5;389:67-75. Epub 2018 Feb 5.

Department of Neurology, Columbia University Medical Center, New York, USA.

Background: Management of tardive syndromes (TS) is challenging, with only a few evidence-based therapeutic algorithms reported in the American Academy of Neurology (AAN) guideline in 2013.

Objective: To update the evidence-based recommendations and provide a practical treatment algorithm for management of TS by addressing 5 questions: 1) Is withdrawal of dopamine receptor blocking agents (DRBAs) an effective TS treatment? 2) Does switching from typical to atypical DRBAs reduce TS symptoms? 3) What is the efficacy of pharmacologic agents in treating TS? 4) Do patients with TS benefit from chemodenervation with botulinum toxin? 5) Do patients with TS benefit from surgical therapy?

Methods: Systematic reviews were conducted by searching PsycINFO, Ovid MEDLINE, PubMed, EMBASE, Web of Science and Cochrane for articles published between 2012 and 2017 to identify new evidence published after the 2013 AAN guidelines. Articles were classified according to an AAN 4-tiered evidence-rating scheme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.010DOI Listing
June 2018
12 Reads
2.470 Impact Factor

The nosology of tardive syndromes.

J Neurol Sci 2018 06 6;389:10-16. Epub 2018 Feb 6.

Parkinson's Disease and Movement Disorders Center, Departments of Neurology, Molecular Pharmacology and Physiology, University of South Florida, Tampa, FL 33613, United States.

Since the original description of side effects of neuroleptics, different terminologies and definitions for tardive dyskinesia (TD) and tardive syndrome (TS) have been used by different authors, and often these two terms have been used interchangeably. This paper proposes a nosology designed to define and clarify various terms and phenomenologies within the TS spectrum. We propose to use the term tardive dyskinesia to refer to the original description of repetitive and complex oral-buccal-lingual (OBL) movements, as well as to the analogous repetitive movements that can appear in the limbs, trunk, or pelvis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.008DOI Listing
June 2018
36 Reads

Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis.

J Neurol Sci 2018 06 5;389:55-60. Epub 2018 Feb 5.

Department of Neurology, Universitätsklinikum Schleswig-Holstein, Kiel Campus, Germany; Christian-Albrechts Universität, Kiel, Germany. Electronic address:

Among the broad entity of tardive syndromes, tardive dystonia and classical tardive dyskinesia sometimes require advanced treatments like deep brain stimulation of the globus pallidus internum (Gpi-DBS) or the subthalamic nucleus (STN-DBS). This systematic review has analyzed the currently available literature reporting cases with either tardive dystonia or dyskinesia treated with DBS. The key words for the literature search included all tardive syndromes and "deep brain stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.02.013DOI Listing
June 2018
8 Reads

Acute Cervical Dystonia Induced by Clebopride.

Case Rep Neurol Med 2017 28;2017:2834349. Epub 2017 Nov 28.

Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.

Antidopaminergic drugs are known to induce extrapyramidal symptoms. Clebopride, a dopamine antagonist, also can produce parkinsonism, tardive dyskinesia, tardive dystonia, hemifacial dystonia, or oculogyric crisis; however, acute dystonic reaction caused by clebopride has not been reported in adults. We report two young men who experienced acute cervical dystonia within a few days of taking clebopride. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2834349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733119PMC
November 2017
13 Reads

Patient Evaluation and Selection for Movement Disorders Surgery: The Changing Spectrum of Indications.

Prog Neurol Surg 2018 12;33:80-93. Epub 2018 Jan 12.

This report summarizes the state-of-the-art and controversies around patient selection for deep brain stimulation (DBS) for various conditions. Parkinson's disease (PD): several class I studies have shown superiority of DBS over best medical treatment for advanced PD with fluctuations and further inclusion criteria. One class I study suggests that PD patients with early motor complications might gain more quality of life if operated within 3 years after the onset of fluctuations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000480910DOI Listing
August 2018
9 Reads

Clinical and Phenomenological Characteristics of Patients with Task-Specific Lingual Dystonia: Possible Association with Occupation.

Authors:
Kazuya Yoshida

Front Neurol 2017 11;8:649. Epub 2017 Dec 11.

Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, Kyoto, Japan.

Background: Lingual dystonia is a subtype of oromandibular dystonia, which is a movement disorder characterized by involuntary sustained or intermittent contraction of the masticatory and/or tongue muscles. Lingual dystonia interferes with important daily activities, such as speaking, chewing, and swallowing, resulting in vocational and social disability.

Objective: The aim of this study was to investigate a possible relationship between occupation and the development of lingual dystonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2017.00649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732148PMC
December 2017
14 Reads

[Symptoms and Pathophysiology of Dyskinesias].

Brain Nerve 2017 Dec;69(12):1409-1416

Department of Neurology, Aomori Prefectural Central Hospital.

Symptomatic characteristics and recent advances in understanding the pathophysiology of tardive dyskinesias and levodopa-induced dyskinesias were reviewed. After the advent of atypical antipsychotics, tardive dyskinesias became less frequent, at least as observed during a short-term follow up. The dopamine supersensitivity hypothesis stating that blockade of dopamine D2 receptors by antipsychotics makes D2 receptors more sensitive to dopamine, has long been proposed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416200926DOI Listing
December 2017
5 Reads

Hallucination: A rare complication of levetiracetam theraphy.

North Clin Istanb 2017 18;4(3):267-269. Epub 2017 Oct 18.

Department of Pediatric Critical Care, Gaziantep University, Gaziantep, Turkey.

Levetiracetam is a new antiepileptic drug. In addition to epilepsy, it is also used for treating anxiety disorders and dystonia as well as tardive dyskinesia associated with the use of levodopa and neuroleptic drugs. Phenytoin therapy in a 10-year-old boy with convulsions was discontinued following cardiac rhythm impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14744/nci.2017.44366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724923PMC
October 2017
8 Reads

Movement disorders and chronic psychosis: Five new things.

Neurol Clin Pract 2017 Apr;7(2):163-169

Movement Disorders Program (DM), Department of Clinical Neurosciences, University of Calgary, Canada; Department of Clinical and Experimental Medicine (FM), University of Messina, Italy; and Institute of Molecular and Clinical Sciences (FM), St George's University of London, UK.

Purpose Of Review: To discuss selected peer-reviewed research articles published between 2014 and 2016 and highlight 5 clinically relevant messages related to hyperkinetic and hypokinetic movement disorders in patients with chronic psychosis.

Recent Findings: A recent population-based study complemented data from clinical trials in showing increased risk of developing extrapyramidal symptoms with antipsychotic use. A community service-based longitudinal study showed that dopamine transporter imaging could help identify subgroups of patients with parkinsonism associated with antipsychotics with a progressive course, potentially manageable with l-dopa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CPJ.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669418PMC
April 2017
7 Reads

[Bilateral Pallidotomy for Tardive Dystonia:A Case Report].

No Shinkei Geka 2017 Nov;45(11):971-976

Department of Neurosurgery, Tokyo Women's Medical University.

Tardive dystonia is a movement disorder related to the use of dopamine-receptor-blocking drugs. Several reports have shown that deep brain stimulation of the globus pallidus internus(GPi-DBS)is effective in treating tardive dystonia. However, a few reports demonstrated the efficacy of ablation of the GPi(pallidotomy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1436203631DOI Listing
November 2017
8 Reads

Clozapine-associated Pisa syndrome: A rare type of tardive dystonia.

Indian J Psychiatry 2017 Jul-Sep;59(3):390-391

Department of Psychiatry, KMCT Medical College, Calicut, Kerala, India. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_308_16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659097PMC
November 2017
11 Reads

[Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia].

Turk Psikiyatri Derg 2017 ;28(3):208-211

Tardive dystonia (TDt) is a debilitating side effect of long-term antipsychotic treatment. Even though TDt is associated with increased psychiatric morbidity, mortality, and severely decreased quality of life, there are no treatment modalities for TDt. Clozapine has been used as a treatment option for TDt in patients with schizophrenia. Read More

View Article

Download full-text PDF

Source
May 2018
34 Reads

Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia?

Neuropsychiatr Dis Treat 2017 31;13:2327-2330. Epub 2017 Aug 31.

Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Cholinergic hypofunction was believed to be associated with the pathogenesis of tardive dyskinesia, and therefore, anticholinergic treatment might exacerbate the condition. We describe herein a middle-aged male with feeble chewing movements, involuntary rolling motions of the tongue, and abnormally tightened cheeks which developed after consuming different psychotropic medications. These symptoms did not improve after routine treatment for tardive dyskinesia, but responded well to anticholinergic agents, such as scopolamine and benzhexol hydrochloride. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/NDT.S143970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587161PMC
August 2017
9 Reads

An update on new and unique uses of botulinum toxin in movement disorders.

Authors:
Joseph Jankovic

Toxicon 2018 Jun 6;147:84-88. Epub 2017 Sep 6.

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States. Electronic address: http://www.jankovic.org.

The therapeutic applications of botulinum toxin (BoNT) have grown manifold since its initial approval in 1989 by the US Food and Drug Administration (FDA) for the treatment of strabismus, blepharospasm, and other facial spasms. Although it is the most potent biologic toxin known to man, long-term studies have established its safety in the treatment of a variety of neurologic and non-neurologic disorders. This review focuses on some novel and uncommon uses of BoNT in the treatment of movement disorders, such as oromandibular dystonia, including bruxism, anterocollis, camptocormia, tremor, tics, tardive and levodopa-induced dyskinesia, and restless legs syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxicon.2017.09.003DOI Listing
June 2018
23 Reads

Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study.

BMJ Open 2017 Aug 3;7(8):e017406. Epub 2017 Aug 3.

Division of Psychiatry, University College London, London, UK.

Objectives: To measure the incidence of movement side effects of antipsychotic drugs in adults with intellectual disability and compare rates with adults without intellectual disability.

Design: Cohort study using data from The Health Improvement Network.

Setting: UK primary care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2017-017406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724123PMC
August 2017
21 Reads

Chewing-induced facial dystonia: a rare presentation of task-specific dystonia.

BMJ Case Rep 2017 Jul 17;2017. Epub 2017 Jul 17.

Department of Neurology, Sawai Man Singh Medical College and Hospital, Jaipur, Rajasthan, India.

This case is an addition to scarce literature available for a rare condition, chewing-induced task-specific dystonia. The patient was a 63-year-old woman who presented with a 4-year history of progressive difficulty in eating food only during chewing associated with abnormal facial grimaces without any difficulty in drinking, swallowing, speaking or singing. Examination revealed dystonia of facial muscles every time she chewed but absent during drinking and speaking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2016-218956DOI Listing
July 2017
9 Reads

Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.

J Child Adolesc Psychopharmacol 2017 Nov 14;27(9):833-839. Epub 2017 Jul 14.

1 Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy , Gainesville, Florida.

Objective: To examine incidence of adverse health outcomes and associated factors among preschoolers (under age 6) who received antipsychotic treatment through the Florida Medicaid Prior Authorization (PA) program.

Methods: Using Florida's PA registry linked to the state's Medicaid claims data, we ascertained incident outcomes during PA-approved antipsychotic use between April 2008 and September 2015 (7.5 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2017.0006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824663PMC
November 2017
38 Reads

[Tardive movement disorders with antipsychotics – a case of aripirazole-induced tardive dystonia and review of the literature].

Z Kinder Jugendpsychiatr Psychother 2017 07 26;45(4):325-334. Epub 2016 Sep 26.

2 Arzneimittelkommission der Deutschen Ärzteschaft (AkdÄ), Berlin.

Extrapyramidal adverse events (EPS) occur less frequently with second-generation antipsychotics (SGAs) than with first-generation antipsychotics (FGAs). Tardive dyskinesia (TD), but not tardive dystonia (TDt), also seems to occur less often in adults. TD was found to occur less frequently in children and adolescents treated with FGAs than in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/1422-4917/a000460DOI Listing
July 2017
9 Reads

Amisulpride withdrawal dyskinesia: a case report.

Ann Gen Psychiatry 2017 14;16:25. Epub 2017 Jun 14.

Bali Psychiatric Center, No. 33, Huafushan, Bali Dist., New Taipei City, 24936 Taiwan.

Background: The effects of antipsychotic drug withdrawal have been inadequately studied. Case reports have described dyskinesia occurring in patients with several antipsychotics withdrawn, but studies on amisulpride withdrawal dyskinesia are lacking.

Case Presentation: A 63-year-old man, who was diagnosed with schizophrenia at age 49, received amisulpride treatment since age 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12991-017-0148-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471910PMC
June 2017
16 Reads

Long-term follow-up of bilateral subthalamic deep brain stimulation for refractory tardive dystonia.

Parkinsonism Relat Disord 2017 Aug 19;41:58-65. Epub 2017 May 19.

Department of Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:

Background: No effective treatment for tardive dystonia (TD) has been well established. Deep brain stimulation (DBS) can ameliorate motor manifestations in primary dystonia, and may also be an effective approach for TD.

Objectives: This study aimed to illuminate the long-term efficacy and safety of subthalamic nucleus (STN)-DBS in treating TD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2017.05.010DOI Listing
August 2017
35 Reads

Tardive Dystonia Related with Aripiprazole.

Psychiatry Investig 2017 May 16;14(3):380-382. Epub 2017 May 16.

Department of Psychiatry, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Republic of Korea.

Tardive dystonia is characterized by sustained, generally slow involuntary twisting movements. It is estimated to occur at a frequency of 1% to 4% among patients who are taking an antipsychotic agent. Unlike the first generation antipsychotics, the second generation antipsychotics are less likely to cause neuroleptic-induced movement disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4306/pi.2017.14.3.380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440443PMC
May 2017
30 Reads

Bupropion-Induced Acute Dystonia with Dose Escalation and Use of Naranjo Nomogram.

Cureus 2017 Apr 12;9(4):e1157. Epub 2017 Apr 12.

Hematology/Oncology, Tufts Medical Center, Tufts University School of Medicine.

Acute drug-induced dystonia is commonly associated with antipsychotic drugs, antidepressants, antiemetics, and other medications. Bupropion (Wellbutrin and Zyban) is one of the most frequently prescribed antidepressants in the United States and Canada and smoking cessation aid. However, only few reported cases have been published of acute dystonia including dystonia after discontinuation of bupropion and even after a single dose of bupropion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.1157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429148PMC
April 2017
25 Reads

Swallowing Disorders in Schizophrenia.

Dysphagia 2017 08 26;32(4):467-471. Epub 2017 Apr 26.

University of South Florida College of Medicine, Tampa, USA.

Disorders of swallowing are poorly characterized but quite common in schizophrenia. They are a source of considerable morbidity and mortality in this population, generally as a result of either acute asphyxia from airway obstruction or more insidious aspiration and pneumonia. The death rate from acute asphyxia may be as high as one hundred times that of the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00455-017-9802-6DOI Listing
August 2017
46 Reads

Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study.

Ther Adv Neurol Disord 2017 Feb 21;10(2):81-90. Epub 2016 Nov 21.

Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal CEDOC, Nova Medical School/ Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.

Background: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrospective study, we aimed to assess the TBZ effectiveness and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS).

Methods: Qualitative analysis of clinical response was used to estimate TBZ effectiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756285616677004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367646PMC
February 2017
23 Reads

[Early Experience with the VerciseTM DBS System in the Treatment of Dystonic Tremor].

Authors:
Yasushi Miyagi

No Shinkei Geka 2017 Mar;45(3):211-217

Department of Stereotactic and Functional Neurosurgery, Fukuoka Mirai Hospital.

Six cases of dystonic tremor were treated with the VerciseTM deep brain stimulation(DBS)system, which has the multiple independent current control(MICC)technology. The mean preoperative score of Burke-Fahn-Marsden dystonia rating scale was 16.2±9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1436203481DOI Listing
March 2017
10 Reads

Severe Tardive Dystonia on Low Dose Short Duration Exposure to Atypical Antipsychotics: Factors Explored.

Indian J Psychol Med 2017 Jan-Feb;39(1):96-98

Department of Psychiatry, Government Medical College and New Civil Hospital, Surat, Gujarat, India.

Tardive dystonia (TD) is a serious side effect of antipsychotic medications, more with typical antipsychotics, that is potentially irreversible in affected patients. Studies show that newer atypical antipsychotics have a lower risk of TD. As a result, many clinicians may have developed a false sense of security when prescribing these medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0253-7176.198938DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330001PMC
March 2017
13 Reads

High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.

J Clin Psychopharmacol 2017 Apr;37(2):231-238

From the *Innova, GGZ Centraal, Amersfoort; and †Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands.

Background: Drug-related movement disorders (DRMDs) reduce quality of life and contribute to medication noncompliance of patients with psychotic disorders. Little is known about the epidemiology of DRMDs in relatively young patients a few years after onset of psychosis. This is an important period to study, as the impact of the antipsychotic treatment on the long-term potentiation of the neural pathways associated with psychotic disorders and DRMDs is still minimal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCP.0000000000000666DOI Listing
April 2017
48 Reads

Excoriation disorder as a risk factor for deep brain stimulation hardware removal.

J Neurol Sci 2017 02 10;373:342-343. Epub 2017 Jan 10.

Department of Neurology - Movement Disorders, Neurological Institute Carlo Besta, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2017.01.034DOI Listing
February 2017
9 Reads

Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.

Front Psychiatry 2016 26;7:207. Epub 2016 Dec 26.

Parkinson's Disease and Dystonia Research Center, Tokushima University Hospital, Tokushima University, Tokushima, Japan; Department of Neurodegenerative Disorders Research, Graduate School of Medical Sciences, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.

Tardive syndrome (TDS) is a potentially permanent and irreversible hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. Guidelines published by the American Academy of Neurology recommend pharmacological first-line treatment for TDS with clonazepam (level B), ginkgo biloba (level B), amantadine (level C), and tetrabenazine (level C). Recently, a class II study provided level C evidence for use of deep brain stimulation (DBS) of the globus pallidus internus (GPi) in patients with TDS. Read More

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fpsyt.2016.00
Publisher Site
http://dx.doi.org/10.3389/fpsyt.2016.00207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5183634PMC
December 2016
7 Reads